Compare BioNano Genomics Inc (BNGO) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Colgate-Palmolive Company — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Colgate-Palmolive Company trades at $91.1 (market cap $72.84B). The key difference: Colgate-Palmolive Company is far larger — about 5518.2× BioNano Genomics Inc's market cap, and Colgate-Palmolive Company pays a 2.33% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | CL | |
|---|---|---|
Market Cap | $13.20M | $72.84B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $99.14 |
52-Week Low | $1.09 | $74.98 |
Enterprise Value | $15.81M | $79.48B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Colgate-Palmolive (CL) trades at $93.21, up 1.05% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with 60.06% gross margins and 822.05% ROE, though valuation metrics appear elevated with a P/E of 36.13. Recent dividend declarations and positive analyst coverage (42% buy rating) support the defensive stock's appeal amid market rotation into stable cash flow names.
Outlook remains positive with a $97 consensus price target representing 4% upside, though premium valuation and North American segment softness present headwinds. The company's 64-year dividend growth streak and global diversification provide stability, while inflation pressures and competitive threats require monitoring for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
